DAIC

JULY 10, 2024

“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.

Pulmonary 111

Pulmonary Hypertension Pharmacology Biomarkers 111

DAIC

DECEMBER 13, 2023

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators. Pulmonary arterial hypertension is a rare disease, affecting fewer than 100 people per million. Siegel Family Foundation Distinguished Professor and senior author of the study. “We

Pulmonary 105

Pulmonary Hypertension Blood Pressure Research 105

Med Page Today

OCTOBER 7, 2024

(MedPage Today) -- BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an observational cohort study.

Pulmonary 90

Pulmonary Hypertension Outcomes 90

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Medical Xpress - Cardiology

JANUARY 19, 2024

A research team has discovered a possible therapeutic target for pulmonary hypertension.

Pulmonary 83

Pulmonary Hypertension Cardiac Function Research 83

Medical Xpress - Cardiology

MAY 19, 2024

The use of hormone replacement therapy (HRT) may be associated with improved pulmonary hypertension in women, according to research presented at the ATS 2024 International Conference held May 17–22 in San Diego.

Pulmonary 77

Pulmonary Hypertension Research 77

Science Daily - Heart Disease

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a new study.

Pulmonary 87

Pulmonary Hypertension Blood Pressure 87

Med Page Today

DECEMBER 29, 2024

(MedPage Today) -- In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both combination macitentan/tadalafil.

Pulmonary 62

Pulmonary Hypertension 62

Medical Xpress - Cardiology

JULY 8, 2024

Pulmonary hypertension is a very serious disease that leads to heart failure and death in many patients.

Pulmonary 71

Pulmonary Hypertension Physiology Heart Failure 71

Medical Xpress - Cardiology

MAY 2, 2024

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic lung disease, heart failure and death. Blood vessels in the lungs aren't like the others in the body.

Pulmonary 66

Pulmonary Hypertension Heart Failure 66

HCPLive

MARCH 22, 2024

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Pulmonary 64

Pulmonary Hypertension 64

Medical Xpress - Cardiology

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a study led by Cedars-Sinai investigators.

Pulmonary 72

Pulmonary Hypertension Blood Pressure 72

Med Page Today

DECEMBER 12, 2023

(MedPage Today) -- Stable patients with pulmonary vascular disease (PVD) tolerated travel to high altitudes fairly well with frequent monitoring and supplemental oxygen therapy provided as necessary, a field study found. Despite the perceived.

Pulmonary 83

Pulmonary Hypertension 83

Heart BMJ

AUGUST 26, 2024

LEARNING OBJECTIVES Review the diagnostic pathway for pulmonary arterial hypertension (PAH) in congenital heart disease (CHD). Understand and interpret right heart catheterisation data in pulmonary hypertension related to CHD. Recognise the typical presentation of PAH in patients with CHD.

Congenital Heart Disease 52

Congenital Heart Disease Pulmonary Congenital Hypertension 52

All About Cardiovascular System and Disorders

APRIL 7, 2024

Transcript of the video: Now we will discuss a chest X-ray showing antler sign in pulmonary venous hypertension. So, the shape of the upper lobe vessels in venous hypertension, pulmonary venous hypertension, will be resembling the antlers of the stag. You can see the antlers here.

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

All About Cardiovascular System and Disorders

FEBRUARY 2, 2024

Biatrial enlargement with pulmonary venous hypertension

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

American College of Cardiology

JUNE 10, 2024

What is the comparative effectiveness of therapies targeting the different treatment pathways in pulmonary arterial hypertension (PAH)?

Pulmonary 49

Pulmonary Hypertension Article 49

Frontiers in Cardiovascular Medicine

JULY 24, 2024

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

Pulmonary 52

Pulmonary Hypertension Angioplasty Pharmacology 52

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 58

Obesity Pulmonary Hypertension TAVR 58

Medical Xpress - Cardiology

MARCH 29, 2024

Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.

Pulmonary 55

Pulmonary Hypertension 55

American College of Cardiology

JUNE 28, 2024

For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?

Pulmonary 54

Pulmonary Hypertension Article 54

Journal of Cardiothoracic Surgery

AUGUST 20, 2024

This research evaluates the effect of balloon pulmonary angioplasty (BPA) on cardiac electrophysiological changes in patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Angioplasty 52

Angioplasty Pulmonary Hypertension Electrophysiology 52

Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation.

Heart Monitor 52

Heart Monitor Pulmonary Hypertension Angioplasty 52

Heart BMJ

AUGUST 26, 2024

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. Fibrotic obstructions resulting from unresolved pulmonary emboli constitute the major vessel disease component.

Pulmonary 52

Pulmonary Hypertension Biomarkers Angioplasty 52

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Background Pulmonary arterial hypertension (PAH) is a severe and rare disease in the cardiopulmonary system. Its pathogenesis involves vascular remodeling of the pulmonary artery, which results in progressive increases in pulmonary arterial pressure.

Pulmonary 59

Pulmonary Hypertension Heart Failure 59

American College of Cardiology

JANUARY 23, 2024

The goal of the A DUE trial was to compare the safety and efficacy of macitentan/tadalafil combination therapy versus macitentan and tadalafil monotherapies in patients with pulmonary arterial hypertension (PAH).

Pulmonary 49

Pulmonary Hypertension Article 49

American College of Cardiology

JUNE 12, 2024

In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension.

Pulmonary 54

Pulmonary Hypertension Outcomes Article 54

Open Heart

JUNE 8, 2022

Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. Methods We analysed the data of all patients with I/H-PAH admitted to our hospital between 1998 and 2019.

Pulmonary 52

Pulmonary Hypertension Transplant Risk Factors 52

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

If pulmonary hypertension is additionally involved with vasoplegic syndrome, circulation management becomes much more complicated. The aim of this study is to investigate whether pituitrin is beneficial for the postoperative outcomes in patients with pulmonary hypertension undergoing cardiac surgery.

Pulmonary 59

Pulmonary Hypertension Outcomes Circulation 59

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Background High-altitude pulmonary hypertension (HAPH) is a common disease in regions of high altitude where performing right heart catheterization (RHC) is challenging. The development of a diagnostic scoring system is crucial for effective disease screening.

Pulmonary 59

Pulmonary Hypertension Laboratory Risk Factors 59

Circulation

MARCH 7, 2024

Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients with chronic thromboembolic pulmonary disease with and without pulmonary hypertension. Not surprisingly, chronic thromboembolic pulmonary hypertension centers are rapidly initiating balloon pulmonary angioplasty programs.

Angioplasty 45

Angioplasty Pulmonary Hypertension Document 45

Frontiers in Cardiovascular Medicine

MAY 8, 2024

Patients with pulmonary hypertension associated with a left-right shunt include a wide spectrum of pathophysiological substrates, ranging from those characterized by pulmonary over-circulation to those with advanced pulmonary vascular disease.

Congenital Heart Disease 52

Congenital Heart Disease Pulmonary Hypertension Congenital 52

Circulation

JANUARY 12, 2024

BACKGROUND:Pulmonary hypertension, characterized by vascular remodeling, currently lacks curative therapeutic options. The dysfunction of pulmonary artery endothelial cells plays a pivotal role in the initiation and progression of pulmonary hypertension (PH). Circulation, Ahead of Print.

Pulmonary 45

Pulmonary Hypertension Biomarkers Circulation 45

American College of Cardiology

DECEMBER 14, 2023

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

Pulmonary 46

Pulmonary Hypertension Outcomes Article 46

Frontiers in Cardiovascular Medicine

DECEMBER 14, 2023

Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. The estimated pulmonary artery systolic pressure (ePASP ≥ 35 mmHg) measured by echocardiography helps screen PH patients. Early diagnosis of PH is important for clinical treatment.

Pulmonary 64

Pulmonary Hypertension Hospital Outcomes 64

Heart BMJ

MAY 10, 2024

Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. Background PH is frequently found in patients with mitral regurgitation and is associated with lower survival rates. p<0.001).

Bicuspid/Mitral 52

Bicuspid/Mitral Pulmonary Hypertension Outcomes 52